在近期举行的第29届欧洲血液协会（EHA）年会上，EHA前主席、伦敦大学玛丽女王学院Barts癌症研究所血液病中心John Gribben教授凭借其在免疫学研究领域的卓越贡献，荣获何塞·卡雷拉斯（JoséCarreras）奖。《肿瘤瞭望-血液时讯》现场特邀John Gribben教授分享其研究成果和获奖感受。同时，John Gribben教授还介绍了以患者为中心的治疗在血液学领域的重要意义，并强调了全球合作和包容性临床试验的重要性，以推进这一领域发展并为全球患者提供最佳照护。

 

John Gribben教授：我非常荣幸能够获得今年的何塞·卡雷拉斯奖。何塞·卡雷拉斯是一位非常著名的歌剧歌唱家，他因接受了异基因干细胞移植而在血液学界广为人知。他的经历为这一领域带来了极大的关注。后来，他建立了一个慈善基金会，资助血液学研究，包括EHA上这个奖项。我的研究主要集中在血液恶性肿瘤的免疫学方面，特别是为何癌症患者不会对自己的肿瘤产生免疫反应。我们发现白血病或淋巴瘤细胞可以抑制免疫系统，我们的工作旨在逆转这种抑制，利用免疫系统对抗癌症。这项研究在双特异性抗体和CAR-T细胞的开发中具有基础性作用。能够获得这一认可，证明了我们在这一领域的努力是值得的。

 

Oncology Frontier-Hematology Frontier：First of all，congratulations on winning the Jose Carreras Award this year.The Jose Carreras Award is one of the most significant awards in the field of hematology.Could you please introduce your outstanding research and share your feelings about winning the award?

 

Professor John Gribben：I’m very honored to have received this year’s Jose Carreras Award.Jose Carreras，a very famous opera singer，is well-known in hematology for having received an allogeneic stem cell transplant.His experience brought significant attention to the field.He later established a charitable foundation that funds research in hematology，including this award.My research has focused on the immunology of hematological malignancies，particularly why cancer patients do not develop an immune response against their own cancer.We found that leukemia or lymphoma cells can suppress the immune system，and our work has aimed to reverse this suppression to use the immune system in the fight against cancer.This research has been foundational in the development of bispecific antibodies and CAR T-cells.It is gratifying to receive this recognition for our efforts in this area.

 

John Gribben教授：我主持了一个与淋巴瘤基金会（这是一个患者倡导组织）合作的专场会议。在我担任EHA主席期间，我致力于增加患者参与我们的工作。该专场会议重点讨论了复发/难治性慢性淋巴细胞白血病（CLL），并探讨了结合疾病生物学、治疗方法和患者偏好的综合治疗方案。现在我们有多种CLL的治疗选择，重要的是让患者参与决定他们更倾向的治疗方法。这种参与提高了患者的依从性和生活质量，是我们治疗方案的关键组成部分。

 

Oncology Frontier-Hematology Frontier：At this conference，you also served as the chairperson for one section.Could you share some of the highlights from this section?

 

Professor John Gribben：I chaired a session with the Lymphoma Foundation，a patient advocacy group.During my time as EHA president，I worked to increase patient involvement in our work.The session focused on relapsed refractory chronic lymphocytic leukemia(CLL)and discussed integrating the biology of the disease，treatment approaches，and patient preferences to develop the best treatment plans.We now have multiple treatment options for CLL，and it is important to involve patients in deciding which treatments they prefer.This engagement improves adherence and quality of life，making it a crucial component of our approach.

 

John Gribben教授：全球合作至关重要。我们需要避免重复临床试验，利用现有知识。历史上，欧洲和美国之间的合作非常紧密。现在，随着医学的全球化和中国在CAR-T细胞开发中的崛起，涉及全球范围的合作变得至关重要。在我担任EHA主席期间，我们与中国血液学会建立了密切的联系，这是合作的一个很好的例子。此外，了解不同种族患者对治疗的反应差异也很重要。将多样化人群纳入临床试验可以揭示药物疗效和毒性的差异，有助于更有效地定制治疗方案。

 

Oncology Frontier-Hematology Frontier：Currently，the field of hematology is undergoing robust development.What efforts should we make to further promote global cooperation and exchange in hematology?

 

Professor John Gribben：Global cooperation is crucial.We need to avoid duplicating clinical trials and leverage existing knowledge.Historically，collaboration has been strong between Europe and the United States.Now，with the globalisation of medicine and China’s emergence as a leader in CAR T-cell development，it is essential to involve the whole world.While I was EHA president，we established close associations with the Chinese Hematology Society，which is a great example of this collaboration.Additionally，understanding ethnic differences in patient responses to treatments is important.Including diverse populations in clinical trials can reveal differences in drug efficacy and toxicity，helping to tailor treatments more effectively.

 

专家简介